BPC-157
Evidence: ★★★☆☆ · Status: Not Approved
In plain English
It tells injured tissue to grow a fresh blood supply (via the VEGFR2 switch), and blood flow is what healing runs on — so tendons, ligaments, gut lining and muscle appear to mend faster. The catch: almost all the evidence is in rats. Human trials essentially don't exist yet, which is why the FDA status is unsettled.
How it works
A 15-amino-acid fragment of a gastric protein. Two characterised pathways: (1) upregulates VEGFR2 (KDR) → PI3K/Akt → eNOS (NOS3), driving angiogenesis (new blood vessels to injured tissue); (2) a Src–Caveolin-1–eNOS route. It also modulates the nitric-oxide system and growth-hormone-receptor expression in tendon fibroblasts.
Molecular target & official sources
KDR/VEGFR2 (NCBI Gene) · NOS3 eNOS (NCBI Gene) · Mechanism paper (Nature Sci Reports) · Narrative review (PMC 2025)
Watch out
No human safety data; theoretical tumour-angiogenesis concern; unregulated product purity.
Bottom line
The most promising healing peptide by animal data — and the biggest human-evidence gap. Watch the July 2026 PCAC decision.
Helps with: Build Muscle & Strength · Recover Faster · Joint Health · Hormones & Testosterone · Gut Health
Stacks with
Shares a pathway — often paired with: Caffeine, PDE-5 Inhibitors (Sildenafil / Tadalafil), EPO (Erythropoietin), Minoxidil.
Availability & where to buy
Not widely approved. Not approved for general sale in most markets (Singapore included). Grey-market only — dose, purity and legality uncertain.
How it works: the Nitric oxide / cGMP pathway →
Used in these protocols
Compare BPC-157
Common questions
Does BPC-157 actually work?
Human-evidence rating: 3 of 5. The most promising healing peptide by animal data — and the biggest human-evidence gap. Watch the July 2026 PCAC decision.
What are the risks or side effects of BPC-157?
No human safety data; theoretical tumour-angiogenesis concern; unregulated product purity.
Is BPC-157 legal or approved?
Regulatory status: Not Approved.